Exelixis
EXEL
#1537
Rank
A$20.30 B
Marketcap
A$81.95
Share price
-0.22%
Change (1 day)
34.80%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): A$4.67

According to Exelixis's latest financial reports the company's current EPS (TTM) is A$4.40. In 2025 the company made an earnings per share (EPS) of A$4.06.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)A$4.6715%
2025A$4.06
2023A$0.9214.61%
2022A$0.80-22.97%
2021A$1.04100%
2020A$0.52-65.09%
2019A$1.49-53.91%
2018A$3.23333.96%
2017A$0.74-260.61%
2016A-$0.46-58.75%
2015A-$1.12-42.45%
2014A-$1.955.3%
2013A-$1.85

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
A$12.27 179.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
A$1.84-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
A$20.33 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
A$3.59-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
A$5.02 14.21%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
A$5.00 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
A$5.46 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
A-$33.42-860.38%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
A-$1.18-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA